Tesa/Ipa CJC Blend: What's in It and How It Works

The tesa/ipa cjc blend is a research peptide combination that puts tesamorelin, ipamorelin, and CJC-1295 into a single lyophilized vial. Each ingredient triggers growth hormone release through a different receptor pathway, which is why researchers study the trio together instead of alone. No regulatory agency has approved this three-peptide combination for human use, and only one of the three ingredients has any FDA-approved indication.

What Is in a Tesa/Ipa/CJC Blend?

Blend vials typically contain all three peptides in a fixed ratio, which removes the need to draw from separate vials but also removes your ability to adjust one peptide independently. Total vial sizes usually range from 5 mg to 15 mg, and ratios vary widely by vendor — some formulas lean heavier on tesamorelin, others on CJC-1295.

Most tesa ipa blend peptide products sold for research use list CJC-1295 without DAC, also known as mod GRF 1-29, because the no-DAC version has a much shorter half-life than the DAC version.

Peptide	Class	Receptor It Targets	Key Research Note
Tesamorelin	GHRH analog	GHRH receptor	The only ingredient with FDA approval, and only for a specific clinical condition
CJC-1295 (no DAC)	GHRH analog (mod GRF 1-29)	GHRH receptor	Short half-life; studied for extending the GH pulse
Ipamorelin	Selective ghrelin receptor agonist	GHS-R1a	Considered selective for GH release in animal models

Why Researchers Combine a GHRH Analog with a Ghrelin Mimetic

Growth hormone release is controlled by two opposing signals: GHRH turns it on, and somatostatin turns it off. Tesamorelin and CJC-1295 act on the GHRH receptor, while ipamorelin acts on the ghrelin receptor. Because the two pathways use separate receptors, they can amplify each other rather than compete for the same binding site.

Ipamorelin is often described as the most selective of the older ghrelin mimetics, meaning it appears to trigger GH release with less impact on cortisol and prolactin than GHRP-2 or GHRP-6 in animal studies. That selectivity is a large part of why it appears in so many blend formulations.

Reported Tesa Ipa Blend Benefits in the Literature

The evidence base is uneven, and it matters which ingredient you are reading about.

• Tesamorelin: the strongest human dataset of the three. Phase 3 trials in HIV-associated lipodystrophy showed reductions in visceral adipose tissue, which is the basis for its approved indication.
• CJC-1295 (no DAC): research focuses mainly on pharmacokinetics and GH pulse duration rather than clinical outcomes.
• Ipamorelin: mostly animal data on selective GH release; controlled human outcome trials are scarce.

Most of what circulates as tesa ipa blend benefits online comes from stacking logic and animal data, not from controlled human trials of the blend itself. A GHRH analog plus a ghrelin mimetic may produce a larger GH pulse than either alone, but that is a reasonable hypothesis rather than a proven clinical result.

CJC/Ipa vs Tesa/Ipa: Which Blend Is Which?

When researchers compare cjc/ipa vs tesa/ipa, the trade-off usually comes down to cost and human data against theoretical pulse duration.

Feature	CJC-1295 + Ipamorelin	Tesamorelin + Ipamorelin	Tesa/Ipa/CJC Blend
Components	2 peptides	2 peptides	3 peptides
Human clinical data	Limited	Moderate (tesamorelin trials)	None for the combination
Typical cost	Lower	Higher	Highest
Theoretical GH pulse	Moderate	Moderate to long	Longest
Common vial size	5-10 mg	5-15 mg	5-15 mg

Typical Tesa Ipa Blend Protocol Discussions

A common tesa ipa blend protocol discussed online involves one subcutaneous injection daily, usually before bed, timed to the body's natural overnight GH pulse. Numbers repeated in forums include roughly 1 mg tesamorelin, 200-300 mcg ipamorelin, and 100-300 mcg CJC-1295 (no DAC) per injection.

Those figures are community conventions, not established dosing, and they do not come from trials of the blend. Some users describe cycling schedules and others inject continuously; there is no comparative research showing one approach is better.

Threads on tesa/ipa blend reddit tend to focus on injection timing, hunger after dosing, and whether splitting the dose morning and night changes anything. Personal anecdotes are not evidence, and reported experiences vary enormously between individuals.

Reconstitution and Storage Basics

Lyophilized peptides must be mixed with bacteriostatic water before use. The volume you add determines concentration, not the total dose in the vial, so the math matters.

1. Swab the stopper of both vials with alcohol and let them dry.
2. Draw bacteriostatic water and inject it slowly against the glass wall, not directly onto the powder.
3. Swirl gently until dissolved. Never shake a peptide vial, because agitation can damage the peptide chains.
4. Refrigerate at 2-8°C and protect from light.

For a step-by-step walkthrough with concentration math, see our guide to tesa/ipa blend reconstitution. Most sources suggest using a reconstituted blend within a few weeks, and none of these products should be stored in a freezer after mixing.

Safety, Sourcing, and Legal Status

Tesamorelin is FDA-approved only as Egrifta for HIV-associated lipodystrophy. CJC-1295 and ipamorelin are not approved for human use in the United States, and the combination product has no approved status anywhere.

Reported side effects across this peptide class include injection-site reactions, water retention, joint discomfort, headache, and increased hunger. Growth hormone secretagogues can also raise IGF-1, which is one reason clinicians monitor bloodwork rather than relying on how someone feels.

Anyone considering these compounds should talk with a licensed healthcare professional, especially if they have a history of cancer, diabetes, or pituitary disease. Vials labeled "research use only" are not manufactured to pharmaceutical standards, and purity varies between vendors.

Key takeaway: the tesa/ipa cjc blend is a research-only combination, and only tesamorelin has FDA approval for a single, narrow indication.

Bottom Line

The tesa/ipa cjc blend stacks a GHRH analog with a selective ghrelin mimetic, and the combination is studied for a larger, longer GH pulse than any single peptide produces alone. Tesamorelin carries the only real human outcome data, CJC-1295 (no DAC) is used mostly for pulse duration, and ipamorelin is chosen for receptor selectivity. None of that makes the blend itself proven, FDA-approved, or safe for unsupervised use.

COMMON QUESTIONS

Frequently Asked Questions

Is the tesa/ipa cjc blend FDA-approved?

No. The combination product is not FDA-approved for any use. Only tesamorelin, sold as Egrifta, holds FDA approval, and that approval covers a single indication: reducing excess abdominal fat in adults with HIV-associated lipodystrophy. CJC-1295 and ipamorelin are not approved for human use in the United States.

How do you reconstitute and store a tesa/ipa cjc blend?

Add bacteriostatic water slowly against the inside wall of the vial, then swirl gently until the powder dissolves. Never shake the vial, because agitation can degrade the peptides. Store the reconstituted blend refrigerated at 2-8°C, protected from light, and use it within a few weeks rather than months.

What is the difference between cjc/ipa and tesa/ipa?

CJC-1295 plus ipamorelin pairs a short-acting GHRH analog with a ghrelin mimetic, while tesamorelin plus ipamorelin swaps in the peptide that has actual human clinical trial data. Tesamorelin blends usually cost more. Adding all three, as in a tesa/ipa cjc blend, is a theoretical attempt to combine both GHRH analogs with ipamorelin, but no controlled human study has tested that combination.